as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 28 Sep 2026
₹1,102.55
Change
+0.0 (0.0%)
Open
₹1,108.0
Prev. Close
₹1,102.55
Day High
₹1,138.95
Day Low
₹1,085.45
Volume Analysis
Traded
116,391
Delivered
44,175
Delivery %
37.95%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (0)
No signal for this stock
Weaknesses (0)
No signal for this stock
Opportunities (3)
- •Strong 3-year EPS growth (16.3%)
- •Strong 3-year revenue growth (20.8%)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹1,186.01 | ₹1,162.48 | ₹1,132.51 | ₹1,108.98 | ₹1,079.01 | ₹1,055.48 | ₹1,025.51 |
| Fibonacci | ₹1,162.48 | ₹1,142.04 | ₹1,129.42 | ₹1,108.98 | ₹1,088.54 | ₹1,075.92 | ₹1,055.48 |
| Camarilla | ₹1,117.26 | ₹1,112.36 | ₹1,107.45 | ₹1,108.98 | ₹1,097.65 | ₹1,092.74 | ₹1,087.84 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+37.53%
1 Week
+0.02%
1 Month
+10.42%
3 Months
+28.05%
6 Months
+44.22%
1 Year
+21.47%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹441.41
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
11.39%
Net margin 7.3% × asset turnover 1.0x × equity multiplier 1.56x
Company Overview
Sector
Healthcare
Market Cap
₹2,275 Cr
P/E (TTM)
34.2
ROE
12.2%
Book Value
₹275.0
Face Value
₹5.0
Source: Screener.in (Consolidated figures) — data as of 28 Sep 2026. Not investment advice.
TopFund Analysis
Windlas Biotech Limited holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 69/100. The strongest factor is Financial Strength (100/100), while Institutional Ownership (38/100) is the weakest area to weigh before deciding. Strong 3-year EPS growth (16.3%).
TopFund Score — Fundamentals Quality
69/100 — GoodData confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 28 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company is almost debt free.
- +Company has been maintaining a healthy dividend payout of 19.7%
- +Promoter holding has increased by 1.41% over last quarter.
- +Company's working capital requirements have reduced from 21.3 days to 14.4 days
- −Company has a low return on equity of 12.8% over last 3 years.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Trading window closed from October 1, 2026 until 48 hours after Q2 FY2027 results.
Intimation of Schedule of Analyst/Institutional Investor Meetings under the SEBI (LODR), Regulations 2015
Audio recording of June 30, 2026 results conference call uploaded; transcript to follow.
Windlas Biotech reported Q1 FY27 revenue of Rs 248 crore, PAT Rs 25 crore, and completed a Rs 47 crore buyback.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 141 | 145 | 153 | 162 | 171 | 175 | 187 | 195 | 203 | 210 | 222 | 233 | 238 |
| Expenses + | 124 | 128 | 134 | 142 | 149 | 154 | 164 | 170 | 177 | 184 | 194 | 209 | 213 |
| Operating Profit | 16 | 17 | 19 | 20 | 22 | 21 | 23 | 25 | 26 | 27 | 29 | 24 | 25 |
| OPM % | 12.0% | 12.0% | 12.0% | 13.0% | 13.0% | 12.0% | 12.0% | 13.0% | 13.0% | 13.0% | 13.0% | 10.0% | 11.0% |
| Other Income + | 2 | 3 | 3 | 3 | 4 | 4 | 5 | 4 | 5 | 5 | 4 | 5 | 4 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 4 | 3 | 3 | 3 | 4 | 6 | 6 | 7 | 8 | 7 | 8 | 8 | 8 |
| Profit before tax | 15 | 16 | 18 | 20 | 23 | 18 | 20 | 20 | 21 | 23 | 24 | 20 | 20 |
| Tax % | 24.0% | 26.0% | 23.0% | 24.0% | 25.0% | 26.0% | 23.0% | 23.0% | 22.0% | 24.0% | 25.0% | 25.0% | 21.0% |
| Net Profit + | 11 | 12 | 14 | 15 | 17 | 13 | 16 | 16 | 16 | 18 | 18 | 15 | 16 |
| EPS in Rs | 5 | 6 | 7 | 7 | 8 | 6 | 7 | 7 | 8 | 8 | 8 | 7 | 8 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Sales + | 352 | 307 | 329 | 428 | 466 | 513 | 631 | 760 | 904 |
| Expenses + | 313 | 270 | 295 | 373 | 414 | 453 | 553 | 666 | 799 |
| Operating Profit | 39 | 38 | 34 | 55 | 52 | 60 | 78 | 94 | 105 |
| OPM % | 11.0% | 12.0% | 10.0% | 13.0% | 11.0% | 12.0% | 12.0% | 12.0% | 12.0% |
| Other Income + | 4 | 54 | 2 | -19 | 7 | 10 | 13 | 18 | 18 |
| Interest | 6 | 5 | 3 | 1 | 1 | 1 | 1 | 4 | 5 |
| Depreciation | 17 | 11 | 9 | 13 | 12 | 12 | 13 | 28 | 31 |
| Profit before tax | 20 | 76 | 25 | 22 | 46 | 57 | 77 | 80 | 87 |
| Tax % | 44.0% | 16.0% | 34.0% | 28.0% | 16.0% | 25.0% | 25.0% | 24.0% | 24.0% |
| Net Profit + | 11 | 64 | 16 | 16 | 38 | 43 | 58 | 61 | 66 |
| EPS in Rs | 20 | 100 | 25 | 25 | 17 | 20 | 28 | 29 | 31 |
| Dividend Payout % | 0.0% | 0.0% | 0.0% | 0.0% | 20.0% | 20.0% | 20.0% | 20.0% | 20.0% |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Reserves | 119 | 187 | 203 | 193 | 384 | 392 | 440 | 495 | 570 |
| Borrowings + | 57 | 32 | 29 | 32 | 7 | 5 | 4 | 33 | 35 |
| Other Liabilities + | 107 | 73 | 100 | 65 | 90 | 122 | 173 | 222 | 291 |
| Total Liabilities | 290 | 298 | 338 | 296 | 491 | 529 | 626 | 760 | 907 |
| Fixed Assets + | 86 | 64 | 70 | 96 | 91 | 109 | 179 | 223 | 213 |
| CWIP | 53 | 5 | 0 | 0 | 8 | 15 | 6 | 5 | 60 |
| Investments | 23 | 122 | 116 | 23 | 65 | 107 | 173 | 223 | 268 |
| Other Assets + | 128 | 107 | 152 | 177 | 327 | 298 | 268 | 308 | 366 |
| Total Assets | 290 | 298 | 338 | 296 | 491 | 529 | 626 | 760 | 907 |
| Equity Capital | 6 | 6 | 6 | 6 | 11 | 10 | 10 | 10 | 11 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 35 | 19 | 25 | 11 | 9 | 61 | 109 | 68 | 105 |
| Cash from Investing Activity + | -11 | -7 | -14 | -20 | -155 | -14 | -92 | -74 | -92 |
| Cash from Financing Activity + | -26 | -6 | -5 | 1 | 130 | -44 | -15 | 1 | -13 |
| Net Cash Flow | -2 | 6 | 5 | -8 | -15 | 3 | 2 | -5 | 0 |
| CFO/OP | 102 | 81 | 113 | 33 | 34 | 117 | 163 | 95 | 115 |
| Free Cash Flow | 10 | 10 | 10 | 6 | -6 | -9 | 71 | 16 | 37 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 24.85% | 24.11% | 24.19% | 25.55% | 25.91% | 25.67% | 25.25% | 25.01% | 25.48% | 25.64% | 25.69% | 24.8% |
| Promoters | 62.82% | 62.82% | 62.82% | 62.51% | 62.51% | 62.51% | 62.34% | 62.34% | 61.98% | 61.98% | 61.9% | 63.31% |
| FII | 0.8% | 1.35% | 1.18% | 1.59% | 2.0% | 1.55% | 1.52% | 1.44% | 1.11% | 0.93% | 0.6% | 2.04% |
| DII | 11.52% | 11.71% | 11.82% | 10.35% | 9.58% | 10.26% | 10.89% | 11.22% | 11.44% | 11.44% | 11.8% | 9.84% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Windlas Biotech Limited (this stock) | 2,275 | 34.2 | 4.01 | 12.2% |
| Panacea Biotec Ltd | 2,282 | — | 2.74 | -2.42% |
| Beta Drugs Limited | 2,262 | 49.6 | 8.46 | 18.8% |
| Fredun Pharmaceuticals L | 2,294 | 52.4 | 8.16 | 15.6% |
| Indoco Remedies Ltd. | 2,306 | — | 2.45 | -9.36% |
| Venus Remedies Limited | 2,230 | 19.2 | 3.36 | 16.8% |
| Sai Parenterals Limited | 2,226 | 107.0 | — | 4.88% |
Which Mutual Funds Hold Windlas Biotech Limited?
Frequently Asked Questions about Windlas Biotech Limited
Windlas Biotech Limited (WINDLAS) closed at ₹1,102.55 on NSE on 28 September 2026, up 0.0 (0.0%) from the previous close.
Windlas Biotech Limited trades on the NSE (National Stock Exchange of India) under the symbol WINDLAS.
Windlas Biotech Limited has a trailing twelve-month P/E (price-to-earnings) ratio of 34.2.
Windlas Biotech Limited has a dividend yield of 0.57%.
Windlas Biotech Limited's 52-week high is ₹1,182.0 and its 52-week low is ₹697.0.
Windlas Biotech Limited has a market capitalisation of ₹2,275 crore.
Windlas Biotech Limited has a TopFund Quality Score of 69/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Windlas Biotech Limited?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.